On the stock market since 1980, it operates in the world of health and science. It has 66,841 employees. Now — the numbers.
This is an established company with proven profits.
The gap is $14.3B. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 15% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 7 buys and 1 sell. Management buying with its own money is usually read as a good sign.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, GSK sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GSK is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.